BBB Foods (NYSE:TBBB) Stock

BBB Foods

BBB Foods Inc is a company offering grocery hard discount model in Mexico. Also that operates through three subsidiaries namely Tiendas Tres B , Tiendas BBB and Desarrolladora Tres BSA de CV of which the main activity of Tiendas Tres B is the sale, purchase, distribution and marketing of all types of products, items and goods, as well as the establishment, and operation of individual stores and distribution centers for the sale of such products.

Wall Street ai6

Earnings Beats

Earnings Misses

Equities

Large Cap

Macro Economic Events

Macro Notification

Market Summary

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Small Cap

Econ #s

Economics

Tech

ETFs

ASML

CSWI

CVCO

SPDR Dow Jones Industrial Average ETF Trust

HLNE

INTU

PAGS

ROST

SNOW

SNPS

STEP

TBBB

iShares Trust Barclays 20+ Year Treasury Bond Fund

WDAY

Strong earnings and revenue guidance from Nvidia sparked a tech stock surge, with Nasdaq 100 and S&amp;P 500 hitting record highs.

Nvidia&#39;s 10% Leap Propels Tech Indexes To Record Highs; Blue Chips, Small Caps Slip: What&#39;s Driving Markets Thursday?

xr:d:DAFj7f9vwuY:2,j:5446957451,t:23052513

News

Intraday Update

Markets

Movers

Trading Ideas

ACIU

AILE

BCYC

BORR

CDLR

CINT

DAVA

DELL

ERAS

NVDA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

RAMP

e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday

Bull and bear stock market index

Bonds

Treasuries

Federal Reserve

$BTC

ENPH

FSLR

GOGL

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

SPWR

TSLA

VSAT

Wall Street experienced a muted session on Wednesday morning as traders adopted a cautious stance ahead of the Federal Reserve meeting minutes release at 2 p.m. EDT and Nvidia Corp.

Stocks Falter, Metals Fall As Traders Turn Cautious Ahead Of Fed Minutes, Nvidia Earnings; First Solar Hits Record Highs: What&#39;s Driving Markets Wednesday?

BBB Foods Inc

Guidance

Herbalife Sees Q1 2025 Revenue (5.5%)-(1.5) YoY

On Wednesday, Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated&nbsp;Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable non-small <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43808682/bristol-myers-squibb-announces-opdivo-plus-chemotherapy-as-the-first-and-only-neoadjuvant-only-imm" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43774882/donald-trumps-tax-cut-could-add-46-trillion-to-deficit-says-robert-reich-emphasizing-48-billion-relief-for-top-100-us-firms-via-corporate-tax-cuts" rel="noreferrer noopener">Trump&#8217;s Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich</a>
The results showed a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.
The results build on the previously reported primary endpoints of event-free survival (EFS) and pathological complete response (pCR), which also met statistical significance.
The safety profile of&nbsp;Opdivo&nbsp;in combination with chemotherapy was consistent with previously reported studies, with no new safety signals observed.
&#8220;The final analysis of overall survival in the CheckMate -816 study underscores the potential of&nbsp;Opdivo&nbsp;in combination with chemotherapy to provide a meaningful survival benefit for patients with resectable NSCLC,&#8221; said Dana Walker, vice president, global program lead, late development, oncology, Bristol Myers Squibb. &#8220;This is the first and only Phase 3 study of a neoadjuvant-only immuno-oncology therapy to show a statistically significant benefit in patients with resectable NSCLC.&#8221;
In October, the FDA approved&nbsp;Bristol Myers&#8217; Opdivo for resectable NSCLC and no known epidermal growth factor&nbsp;receptor mutations or anaplastic lymphoma kinase (ALK) rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy,&nbsp;followed by single-agent&nbsp;Opdivo&nbsp;as adjuvant&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41184042/bristol-myers-10b-cancer-drug-opdivo-scores-expanded-use-fda-approval-for-lung-cancer-in-pre-and-" rel="noreferrer noopener">treatment after surgery</a>.
Last week, Bristol Myers released topline data from its Phase 2 TRANSCEND FL trial of&nbsp;Breyanzi&nbsp;(lisocabtagene maraleucel) for relapsed or refractory indolent B-cell&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43597173/whats-going-on-with-bristol-myers-squibb-stock-on-monday" rel="noreferrer noopener">non-Hodgkin lymphoma</a>.
The study met its primary endpoint in the marginal zone lymphoma (MZL) cohort and Breyanzi&nbsp;demonstrated a statistically significant and clinically meaningful overall response rate (ORR) in these patients. It also met the key secondary endpoint of complete response rate (CRR).
Price Action: BMY stock closed higher by 1.01% to $54.98 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43817229/nisun-international-partners-with-gold-of-china-aiming-30-50-million-gold-market-expansion-in-2025" target="_blank" rel="noreferrer noopener">Nisun Partners With Gold Of China To Tap Booming Market: Details</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

General

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer

Farmland Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPI#NYSE">FPI</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.17 by 11.76 percent. This is a 18.75 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $21.47 million which beat the analyst consensus estimate of $20.29 million by 5.82 percent. This is a 0.55 percent decrease over sales of $21.59 million the same period last year.

Earnings

First Trust Advantage Preferred Income Fund

Farmland Partners Q4 FFO $0.19 Beats $0.17 Estimate, Sales $21.47M Beat $20.29M Estimate

Pinstripes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNST#NYSE">PNST</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.13) by 46.15 percent. This is a 157.58 percent decrease over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $35.516 million which missed the analyst consensus estimate of $36.350 million by 2.29 percent. This is a 10.43 percent increase over sales of $32.162 million the same period last year.

PNST

Pinstripes Holdings Q3 2025 GAAP EPS $(0.19) Misses $(0.13) Estimate, Sales $35.516M Miss $36.350M Estimate

IBIO

iBio To Begin Trading On Nasdaq On March 4, 2025 Under "IBIO"

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) sees FY2025 sales of $96.000 million-$98.000 million vs $97.72 million analyst estimate.

LUNG

Pulmonx Sees FY2025 Sales $96.000M-$98.000M vs $97.72M Est

GRI's common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025
LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=MzcPI4Nne-gM9Y7IcrvoQNVonsr-sxSgaMIIl8GMorqA_B5Lg8fWbPdlBY6JIGy97U4a6Zc22KT2nbZICLkmUw==">GRI Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a&nbsp;1-for-17 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on February 11, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 21, 2025. The Company's common stock will open for trading under a new CUSIP number 3622AW 403 on The Nasdaq Capital Market on February 24, 2025, on a split-adjusted basis under the current ticker symbol "GRI." The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Stock Split

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Announces 1-For-17 Reverse Stock Split, Expected To Begin Trading On A Post-Split Adjusted Basis On February 24, 2025

The company's SEMVision&#x2122; H20 system combines the industry's most sensitive electron beam (eBeam) technology with advanced AI image recognition to enable better and faster analysis of buried nanoscale defects in the world's most advanced chips.

AMAT

Applied Materials Unveils New Chip Defect Review System

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) is looking for Q1 GAAP EPS of $(0.26)-$0.04 vs $0.72 analyst estimate..

Rogers Sees Q1 GAAP EPS $(0.26)-$0.04 vs $0.72 Est

WIIM

INSG

Inseego shares are trading lower. The company reported Q4 financial results.

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) is looking for Q1 Adj EPS of $0.10-$0.40 vs $0.72 analyst estimate. sees sales of $180.000 million-$195.000 million vs $200.20 million analyst estimate.

Rogers Sees Q1 Adj EPS $0.10-$0.40 vs $0.72 Est; Sees Sales $180.000M-$195.000M vs $200.20M Est

Broadstone Net Lease Sees FY25 AFFO $1.45-$1.49 Vs $1.52 Est.

Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 60.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $9.72 million which beat the analyst consensus estimate of $8.77 million by 10.79 percent. This is a 31.65 percent increase over sales of $7.38 million the same period last year.

ENVX

Enovix Q4 Adj EPS $(0.11) Beats $(0.18) Estimate, Sales $9.72M Beat $8.77M Estimate

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.45) by 26.67 percent. This is a 8.33 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $23.77 million which beat the analyst consensus estimate of $22.29 million by 6.61 percent. This is a 23.28 percent increase over sales of $19.28 million the same period last year.

Pulmonx Q4 EPS $(0.33) Beats $(0.45) Estimate, Sales $23.77M Beat $22.29M Estimate

Teekay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TK#NYSE">TK</a>) reported quarterly earnings of $0.19 per share. This is a 45.71 percent decrease over earnings of $0.35 per share from the same period last year. The company reported $256.57 million in sales this quarter. This is a 24.36 percent decrease over sales of $339.19 million the same period last year.

Teekay Q4 Adj EPS $0.19 Down From $0.35 YoY, Sales $256.57M Down From $339.19M YoY

<h4>Key Takeaways:</h4>
<ul>
<li>iMotion Automotive raised HK$228 million through new share placement, three months after raising a smaller HK$73 million</li>
<li>Last month the company entered a strategic tie-up with Horizon Robotics aimed at speeding up sales of its intelligent driving solutions into mass-produced vehicles</li>
</ul>
The surprising release of DeepSeek, a low-cost Chinese AI model, has sent companies racing to integrating the technology into their ecosystems, hoping it will work magic not only for their business but also their stocks.
One group catching the DeepSeek fever is intelligent driving, where the technology promises to improve existing products at far lower costs than previously thought. One such company is&nbsp;iMotion Automotive Technology (Suzhou) Co. Ltd.&nbsp;(1274.HK), whose stock is up 90% over the past month after it entered a strategic cooperation agreement with intelligent driving chip maker&nbsp;Horizon Robotics&nbsp;(9660.HK).
iMotion seized on the rally to raise HK$228 million ($28 million) through a new share placement earlier this month, with 60% of proceeds earmarked for developing high-level autonomous driving and integrated cockpit solutions and products. The fundraising was iMotion&rsquo;s second in the 14 months since its IPO, following one in early December where it raised a smaller HK$73.28 million. Only around HK$11.21 million in funds currently remain from that last fundraising, showing just how quickly iMotion is burning through its cash.
Word of the latest share sale brought iMotion exactly what it was hoping for. After initially dropping nearly 10% at one point on the day of the announcement, the stock powered back and ultimately closed up 4.2% for the day, pushing its valuation to HK$5.77 billion. The company began stoking up its cash pile just a few days earlier with its completion of the float of around 100 million unlisted H-shares on Feb. 6.
Under the latest fundraising, the company planned to issue up to 11.19 million shares to six or more underwriters, representing 4.63% of its enlarged share capital, according to&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0209/2025020900087.pdf">its announcement</a>. At HK$20.88 per share, the placement price represented a discount of about 13% to the HK$24 closing price the day before the announcement. But it was 18.57% higher than the stock&rsquo;s average closing price over the previous five trading days, and 35.06% higher than the previous 20 trading days, showing just how quickly the stock has risen.
<h4>Horizon Robotics collaboration</h4>
iMotion has popped up on investor radar screens as it enters a new high-speed growth stage. Last month, it formed a strategic tie-up with Horizon Robotics that will see the pair co-develop mass-produced intelligent driving solutions based on Horizon&rsquo;s Journey 6E series of chips. iMotion&rsquo;s products have also reportedly been selected exclusively for use in a new model being developed by Geely New Energy, based on Horizon&rsquo;s Journey 6 chip series.
Horizon&rsquo;s Journey 6E chips are among the most cost-efficient computing chips in the intelligent driving space, able to support functions such as high-speed navigation, autonomous parking and city memory navigation at a competitive cost of less than 5,000 yuan for the full suite.
The Horizon collaboration allows iMotion to target the middle end of the intelligent driving market whose vehicles typically sell for between 100,000 yuan ($13,800) and 150,000 yuan. Cars in that range account for 60% to 70% of annual car sales and are highly sought by intelligent driving companies trying to commercialize their products.
<h4>DeepSeek era dawning</h4>
While the Horizon tie-up is bringing real business potential, DeepSeek is also charging up intelligent driving and other automotive stocks with its potential to boost the sector. Since the Lunar New Year, more than 20 automakers, including Geely, Chery, Dongfeng, Great Wall, FAW-Volkswagen and SAIC-GM have begun using the DeepSeek model in their systems, showing the intelligent auto industry has entered a &ldquo;DeepSeek era.&rdquo;
iMotion has also been gearing up for the integration. According to sources familiar with the situation, it has used DeepSeek to test over 200 video clips, achieving solid outcomes and enhanced efficiency. Cars equipped with such DeepSeek technology can achieve more precise target identification, scenario understanding and path planning at the vehicle perception level, ensuring the stable and safe performance of their autonomous driving systems when confronted with complex road conditions. Moreover, DeepSeek&rsquo;s powerful model training and optimizing capabilities also help to improve algorithms and shorten product iteration cycles, thus improving the performance and stability of autonomous driving systems.
iMotion technology systems director Zhang Wei said in a media interview that &ldquo;to put it simply, DeepSeek enables city autonomous driving functions with the same level of performance but with much cheaper training and less data.&rdquo;
iMotion is still running on a capital-intensive model as it competes in a sector where heavy R&amp;D spending is a must and competition to get your products into new mass-produced vehicles is cutthroat. In terms of price-to-sales (P/S) ratio, iMotion stands at 4.4 times, higher than&nbsp;Huizhou Desay SV Automotive&rsquo;s&nbsp;(002920.SZ)&rsquo;s 2.7 times but much lower than the 32 for&nbsp;Black Sesame&nbsp;(2533.HK) and 8.7 times for&nbsp;Mobileye&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbly#NASDAQ">MBLY</a>), indicating the stock has yet to really take off despite its recent rally. That means the stock could have big upside potential if the company can roll out market-defining products that ultimately end up in mass-produced smart cars.
The Chinese intelligent driving technology market is still in its early stages, meaning anyone could still emerge on top if their products prove popular and reliable. With car makers such as XPeng, Nio and Li Auto all on the fast track to deploying intelligent driving technologies, speeding up R&amp;D and enhancing competitiveness are top priorities for not only iMotion but also its peers as they seek to get their products into the latest models. The arrival of DeepSeek and more breakthroughs for large AI models is adding more pressure on companies to differentiate their products and use the latest developments to their advantage. Otherwise, they could risk getting left behind the dust.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

MBLY

iMotion Automotive rides DeepSeek fever to new fundraising

Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.37 by 2.7 percent. This is unchanged from the same period last year. The company reported quarterly sales of $112.130 million which beat the analyst consensus estimate of $110.595 million by 1.39 percent. This is a 6.79 percent increase over sales of $105.000 million the same period last year.

Broadstone Net Lease Q4 2024 FFO $0.36 Misses $0.37 Estimate, Sales $112.130M Beat $110.595M Estimate

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.43 by 6.98 percent. This is a 23.33 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $192.20 million which beat the analyst consensus estimate of $191.75 million by 0.23 percent. This is a 6.06 percent decrease over sales of $204.60 million the same period last year.

Rogers Q4 Adj $0.46 Beats $0.43 Estimate, Sales $192.20M Beat $191.75M Estimate

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.22 by 63.64 percent. This is a 28.57 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $1.20 billion which beat the analyst consensus estimate of $1.19 billion by 0.47 percent. This is a 1.23 percent decrease over sales of $1.22 billion the same period last year.

Herbalife Q4 2024 Adj EPS $0.36 Beats $0.22 Estimate, Sales $1.20B Beat $1.19B Estimate

Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) reported quarterly sales of $48.09 million which beat the analyst consensus estimate of $45.57 million by 5.53 percent. This is a 12.47 percent increase over sales of $42.75 million the same period last year.

Inseego Q4 Sales $48.09M Beat $45.57M Estimate

Press Releases

BBB Foods Inc. Announces the Filing of its Annual Report on Form 20-F for Fiscal Year 2023

TBBB Invites You to Join Its First Quarter 2024 Earnings Conference Call

Tiendas 3B 1Q24 Earnings Release

TBBB Invites You to Join Its Second Quarter 2024 Earnings Conference Call

Tiendas 3B 2Q24 Earnings Release

Join TBBB For Its Third Quarter 2024 Earnings Conference Call

Tiendas 3B 3Q24 Earnings Release

BBB Foods Inc. Announces Proposed Secondary Follow-On

BBB Foods Inc. Announces Pricing of Secondary Offering

BBB Foods Inc. Announces Closing of Secondary Offering

Albertsons Companies, Inc. Class A Common Stock

Albertsons Companies

Maplebear

Caseys General Stores, Inc. - Common Stock

Casey's General Stores

Chanson International Holding - Class A Ordinary Shares

Chanson International

Dingdong (Cayman) Limited American Depositary Shares (each two representing three Ordinary Shares)

Comments

BBB Foods

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga